News By Tag Industry News News By Location Country(s) Industry News
| Cancer: New Inhibitor Effective Where Other Treatments FailInvestigation of targeted treatment in refractory myeloma patients: scientists from Karl Landsteiner University of Health Sciences part of team behind international study.
By: Karl Landsteiner University of Health Sciences Multiple myeloma is the second most common form of hematologic malignancies. Besides autologous stem cell transplantation for fit patients and conventional chemotherapy drugs, three classes of agents, which are optimally combined, form the backbone of myeloma therapy: immunomodulatory drugs (IMiDs), proteasome inhibitors, and monoclonal antibodies. If patients develop resistance against one of these types of medication, they often switch to another. At present, no further drug treatment is available for the increasing number of myeloma patients resistant against all three drug classes thereby precluding further improvement of patient survival. However, an international team including KL Krems' Dr. Klaus Podar (from the Department of Internal Medicine 2, Krems University Hospital) has now uncovered a medication that opens the door to a new treatment option. Original publication: Scientific Contact Priv.-Doz. Mag. DDr. Klaus Podar Department of Internal Medicine 2 University Hospital Krems Karl Landsteiner University of Health Sciences Mitterweg 10 3500 Krems an der Donau T +43 2732 9004 2555 E klaus.podar@ W http://www.krems.lknoe.at Karl Landsteiner University of Health Sciences Eva-Maria Gruber Communication, PR & Marketing (Head) Dr.-Karl-Dorrek- 3500 Krems / Austria T +43 2732 72090 231 M +43 664 5056211 E evamaria.gruber@ W http://www.kl.ac.at/ End
|
|